Keryx Biopharmaceuticals (KERX) Added to GDT::Portfolio

Keryx Biopharmaceuticals (KERX) was added to the GDT::Portfolio on 02016.04.01 (yes, April Fools' Day). We paid $4.55 per KERX share. " Keryx Biopharmaceuticals focuses on providing therapies for patients with renal disease in the United States."

Steven C. Gilman joined the Keryx board on 02016.03.31. Gilman is also on the board of Vericel (VCEL) and VCEL is a GDT::Portfolio stock.